Clinical Trial

Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results

Study acronym: AVS
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 15, 2023 (before its estimated March 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute myeloid leukemia based on MRD results on day 14 of the first cycle.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-02-12.
Status change: Not Yet Recruiting → Recruiting 2023-03-13
Trial Details
NCT Number NCT05736978
Lead Sponsor Shanghai Tong Ren Hospital
Conditions AML, MRD
Enrollment 58 participants
Start Date 2023-03-31
Primary Completion 2025-03-01 (estimated)
Study Completion 2027-03-15 (estimated)
Updated on ClinicalTrials.gov 2023-03-15